ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 265 filers reported holding ROYALTY PHARMA PLC in Q4 2021. The put-call ratio across all filers is 0.25 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $54,037 | -23.4% | 1,991,002 | -13.2% | 0.01% | -20.0% |
| Q2 2023 | $70,532 | -20.9% | 2,294,416 | -7.3% | 0.01% | -23.1% |
| Q1 2023 | $89,210 | -9.9% | 2,475,947 | -1.1% | 0.01% | -18.8% |
| Q4 2022 | $98,979 | -99.9% | 2,504,532 | +6.9% | 0.02% | +6.7% |
| Q3 2022 | $94,135,000 | -4.8% | 2,342,810 | -0.4% | 0.02% | +25.0% |
| Q2 2022 | $98,901,000 | +12.3% | 2,352,542 | +4.0% | 0.01% | +33.3% |
| Q1 2022 | $88,096,000 | -2.9% | 2,261,199 | -0.7% | 0.01% | +12.5% |
| Q4 2021 | $90,761,000 | +14.3% | 2,277,559 | +3.7% | 0.01% | +14.3% |
| Q3 2021 | $79,390,000 | -12.0% | 2,196,736 | -0.1% | 0.01% | -12.5% |
| Q2 2021 | $90,172,000 | -12.2% | 2,199,853 | -6.6% | 0.01% | -20.0% |
| Q1 2021 | $102,691,000 | -36.1% | 2,354,218 | -26.6% | 0.01% | -37.5% |
| Q4 2020 | $160,618,000 | -53.6% | 3,209,155 | -61.0% | 0.02% | -60.0% |
| Q3 2020 | $346,280,000 | -11.1% | 8,231,050 | +2.6% | 0.04% | -18.4% |
| Q2 2020 | $389,491,000 | – | 8,022,471 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $294,957,000 | 88.74% |
| Vantage Consulting Group Inc | 8,705,551 | $379,735,000 | 76.23% |
| Memorial Sloan Kettering Cancer Center | 2,680,644 | $116,930,000 | 72.07% |
| HARVARD MANAGEMENT CO INC | 10,714,284 | $467,357,000 | 26.11% |
| ROBERT WOOD JOHNSON FOUNDATION | 970,151 | $4,231,798,000 | 21.59% |
| Brown University | 381,759 | $16,652,000 | 11.44% |
| Overbrook Management Corp | 771,155 | $33,638,000 | 7.48% |
| SpiderRock Advisors, LLC | 778,800 | $34,236,000 | 4.79% |
| Renaissance Capital LLC | 452,948 | $19,758,000 | 2.93% |
| Lagoda Investment Management, L.P. | 104,835 | $4,573,000 | 2.28% |